Topharman Shanghai Co., Ltd.;Shanghai Institute of Materia Medica, Chinese Academy of Sciences;Topharman Shandong Co., Ltd.
发明人:
申请号：
EP12823704.7
公开号：
EP2746284B1
申请日:
2012.08.14
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.
